SEC Company Response from Arcadia Biosciences, (RKDA) — Jan 27, 2026
Arcadia Biosciences, Inc.
Date: Jan. 27, 2026 · CIK: 0001469443 · Accession: 0001193125-26-025264
AI Filing Summary & Sentiment
Reasoning
Letter
January 27, 2026 Securities and Exchange Commission 100 F Street, NE Washington, DC 20549 Attn: Filing Desk Re: Arcadia Biosciences, Inc. Registration Statement on Form S-3 Ladies and Gentlemen: On behalf of Arcadia Biosciences, Inc. (the “Company”), we submit for filing under the Securities Act of 1933, as amended (the “Act”), a Registration Statement on Form S-3 covering the possible resale by certain selling shareholders of shares of the Company’s Common Stock, pursuant to Rule 415 of the Act, together with certain exhibits thereto. The Company’s common stock is listed on the Nasdaq Capital Market. This filing is being effected by EDGAR. Please note that the Company has wired the filing fee to the account of the Securities and Exchange Commission. T Please call the undersigned at (916) 558-6110, or email the undersigned at kkelso@weintraub.com, with any questions or comments. WEINTRAUB TOBIN CHEDIAK COLEMAN GRODIN Law Corporation /s/ C. Kevin Kelso C. Kevin Kelso
Show Raw Text
CORRESP 1 filename1.htm CORRESP January 27, 2026 Securities and Exchange Commission 100 F Street, NE Washington, DC 20549 Attn: Filing Desk Re: Arcadia Biosciences, Inc. Registration Statement on Form S-3 Ladies and Gentlemen: On behalf of Arcadia Biosciences, Inc. (the “Company”), we submit for filing under the Securities Act of 1933, as amended (the “Act”), a Registration Statement on Form S-3 covering the possible resale by certain selling shareholders of shares of the Company’s Common Stock, pursuant to Rule 415 of the Act, together with certain exhibits thereto. The Company’s common stock is listed on the Nasdaq Capital Market. This filing is being effected by EDGAR. Please note that the Company has wired the filing fee to the account of the Securities and Exchange Commission. T Please call the undersigned at (916) 558-6110, or email the undersigned at kkelso@weintraub.com, with any questions or comments. WEINTRAUB TOBIN CHEDIAK COLEMAN GRODIN Law Corporation /s/ C. Kevin Kelso C. Kevin Kelso